Hansoh Pharma reports Phase 2 ASCO GU 2026 data for risvutatug rezetecan in mCRPC

Reuters08:03

Hansoh Pharma reports Phase 2 ASCO GU 2026 data for risvutatug rezetecan in mCRPC

Hansoh Pharmaceutical Group Co., Ltd. announced that Phase 2 data for risvutatug rezetecan (HS-20093 / GSK5764227), a B7-H3-targeted antibody-drug conjugate, were presented at the 2026 ASCO Genitourinary Cancers Symposium. The ARTEMIS-003 (NCT06001255) open-label, multicenter study is evaluating the drug in patients with metastatic castration-resistant prostate cancer who progressed after at least one prior systemic therapy, using an 8.0 mg/kg dose every three weeks, with objective response rate assessed per combined RECIST v1.1 and PCWG3 criteria as the primary endpoint. In taxane-pretreated patients, the combined objective response rate was 38.9% and the combined PSA50 response rate was 40.7%; in taxane-naïve patients, the unconfirmed objective response rate was 41.7% and the unconfirmed PSA50 rate was 23.8%, with enrollment ongoing and updated results pending. The most common grade 3 or higher treatment-related adverse events reported at an incidence of at least 20% were decreased neutrophil count and anemia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on February 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614958938?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-28 08:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614958938","market":"fut","top_or_hot":-1,"title":"Hansoh Pharma reports Phase 2 ASCO GU 2026 data for risvutatug rezetecan in mCRPC","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hansoh Pharma reports Phase 2 ASCO GU 2026 data for risvutatug rezetecan in mCRPC\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hansoh Pharmaceutical Group Co., Ltd. announced that Phase 2 data for risvutatug rezetecan (HS-20093 / GSK5764227), a B7-H3-targeted antibody-drug conjugate, were presented at the 2026 ASCO Genitourinary Cancers Symposium. The ARTEMIS-003 (NCT06001255) open-label, multicenter study is evaluating the drug in patients with metastatic castration-resistant prostate cancer who progressed after at least one prior systemic therapy, using an 8.0 mg/kg dose every three weeks, with objective response rate assessed per combined RECIST v1.1 and PCWG3 criteria as the primary endpoint. In taxane-pretreated patients, the combined objective response rate was 38.9% and the combined PSA50 response rate was 40.7%; in taxane-naïve patients, the unconfirmed objective response rate was 41.7% and the unconfirmed PSA50 rate was 23.8%, with enrollment ongoing and updated results pending. The most common grade 3 or higher treatment-related adverse events reported at an incidence of at least 20% were decreased neutrophil count and anemia.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on February 28, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hansoh Pharma reports Phase 2 ASCO GU 2026 data for risvutatug rezetecan in mCRPC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHansoh Pharma reports Phase 2 ASCO GU 2026 data for risvutatug rezetecan in mCRPC\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-28 08:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hansoh Pharma reports Phase 2 ASCO GU 2026 data for risvutatug rezetecan in mCRPC\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hansoh Pharmaceutical Group Co., Ltd. announced that Phase 2 data for risvutatug rezetecan (HS-20093 / GSK5764227), a B7-H3-targeted antibody-drug conjugate, were presented at the 2026 ASCO Genitourinary Cancers Symposium. The ARTEMIS-003 (NCT06001255) open-label, multicenter study is evaluating the drug in patients with metastatic castration-resistant prostate cancer who progressed after at least one prior systemic therapy, using an 8.0 mg/kg dose every three weeks, with objective response rate assessed per combined RECIST v1.1 and PCWG3 criteria as the primary endpoint. In taxane-pretreated patients, the combined objective response rate was 38.9% and the combined PSA50 response rate was 40.7%; in taxane-naïve patients, the unconfirmed objective response rate was 41.7% and the unconfirmed PSA50 rate was 23.8%, with enrollment ongoing and updated results pending. The most common grade 3 or higher treatment-related adverse events reported at an incidence of at least 20% were decreased neutrophil count and anemia.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on February 28, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心资产","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260228:nNDL38l6xk:1","article_id":"2614958938","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614958938","pubTimestamp":1772236994,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Hansoh Pharmaceutical Group Co., Ltd. announced that Phase 2 data for risvutatug rezetecan , a B7-H3-targeted antibody-drug conjugate, were presented at the 2026 ASCO Genitourinary Cancers Symposium. The ARTEMIS-003  open-label, multicenter study is evaluating the drug in patients with metastatic castration-resistant prostate cancer who progressed after at least one prior systemic therapy, using an 8.0 mg/kg dose every three weeks, with objective response rate assessed per combined RECIST v1.1 and PCWG3 criteria as the primary endpoint. In taxane-pretreated patients, the combined objective response rate was 38.9% and the combined PSA50 response rate was 40.7%; in taxane-nave patients, the unconfirmed objective response rate was 41.7% and the unconfirmed PSA50 rate was 23.8%, with enrollment ongoing and updated results pending. The most common grade 3 or higher treatment-related adverse events reported at an incidence of at least 20% were decreased neutrophil count and anemia.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1589":"北水核心资产","03692":"翰森制药","BK1583":"高瓴概念","BK1191":"制药"},"translate_title":"翰森制药报告risvutatug rezetecan治疗mCRPC的2期ASCO GU 2026数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":0.9},"content_text":"Hansoh Pharma reports Phase 2 ASCO GU 2026 data for risvutatug rezetecan in mCRPC\n    \n\n        Hansoh Pharmaceutical Group Co., Ltd. announced that Phase 2 data for risvutatug rezetecan (HS-20093 / GSK5764227), a B7-H3-targeted antibody-drug conjugate, were presented at the 2026 ASCO Genitourinary Cancers Symposium. The ARTEMIS-003 (NCT06001255) open-label, multicenter study is evaluating the drug in patients with metastatic castration-resistant prostate cancer who progressed after at least one prior systemic therapy, using an 8.0 mg/kg dose every three weeks, with objective response rate assessed per combined RECIST v1.1 and PCWG3 criteria as the primary endpoint. In taxane-pretreated patients, the combined objective response rate was 38.9% and the combined PSA50 response rate was 40.7%; in taxane-naïve patients, the unconfirmed objective response rate was 41.7% and the unconfirmed PSA50 rate was 23.8%, with enrollment ongoing and updated results pending. The most common grade 3 or higher treatment-related adverse events reported at an incidence of at least 20% were decreased neutrophil count and anemia.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on February 28, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614958938","isCrawlerRequest":true}